Selinexor plus ruxolitinib in JAK inhibitor (JAKi)-naive patients with myelofibrosis: Long term follow up from XPORT-MF-034 suggestive of disease modification

Results from a trial of selinexor (SEL) plus ruxolitinib (RUX) among patients with JAK inhibitor–naïve myelofibrosis, presented during the 2023 American Society of Hematology Annual Meeting, showed that the combination was generally well tolerated and manageable. Evidence of potential disease modification was seen via rapid stabilization of platelets and maintaining hemoglobin levels, variant allele frequency reduction, and pro-inflammatory cytokine reduction.